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Background: The SARS-CoV-2 virus responsible for severe respiratory infection
associated with coronavirus disease 2019 (COVID-19) was first confirmed in Florida
on March 1, 2020. Responding to the pandemic, multi-agency collaborative
partnerships put in place actions integrating point-of-care antibody testing at
established large-scale COVID-19 testing sites where the baseline seropositivity of
COVID-19 in health care workers and first responders in Florida at the start of the
pandemic was established. Purpose: Determine the seropositivity of healthcare
workers and first responders at five drive thru testing sites using a rapid SARS-CoV-2
antibody test in Florida from May 6 through June 3, 2020. Methods: The first drivethru SARS-CoV-2 antibody test site was opened at Miami Hard Rock Stadium, May 6,
2020. Testing expanded to three additional sites on May 9, 2020: Jacksonville,
Orlando, and Palm Beach. The fifth and final site, Miami Beach, began testing on May
21, 2020. Healthcare workers and first responder’s self-seeking SARS-CoV-2 testing
were designated for antibody testing and completed a laboratory collection form onsite for the point-of-care test. All testing was performed on whole blood specimens
(obtained by venipuncture) using the Cellex Inc. qSARS-CoV-2 IgG/IgM Rapid Test.
Seropositivity was assessed by univariate analysis and by logistic regression including
the covariates age, sex, race/ethnicity, and testing location. Results and Discussion:
As of June 3, 2020, of 5,779 healthcare workers and first responders tested, 4.1% were
seropositive (range 2.6–8.2%). SARS-COV-2 antibody tests had higher odds of being
positive for persons testing at the Miami Hard Rock Stadium (aOR 2.24 [95% C.I.
1.48-3.39]), persons of Haitian/Creole ethnicity (aOR 3.28 [95% C.I. 1.23-8.72]),
Hispanic/Latino(a) ethnicity (aOR 2.17 [95% C.I. 1.50-3.13], and Black non-Hispanic
persons (aOR 1.63 [95% C.I. 1.08-2.46]). SARS-COV-2 antibody prevalence among
first responders and healthcare workers in five sites in Florida varied by race and
ethnicity and by testing location.

______________________________________________________________________________________
Introduction | The SARS-CoV-2 virus responsible
for severe respiratory infection associated with
coronavirus infectious disease 2019 (COVID-19) was
first identified and confirmed in Florida on March 1,
2020. Between March 1, 2020 and June 4, 2020,
60,183 persons in Florida were diagnosed with
COVID-19 and 2,607 had COVID-19-associated
mortality.1 Large-scale testing is one of the major
pillars in Florida’s response efforts to detect and
contain the transmission of COVID-19. As of June 4,
2020, over 1,107,000 persons in Florida had been
tested at public health, commercial and hospital
laboratories; results indicated a state positivity rate of
5.3 percent by RT-PCR and 3.6% positivity for
initially tested persons with SARS-CoV-2, as some
persons were retested to determine if virus was still
present.

Following the first persons diagnosed with SARSCoV-2 in Florida, State Surgeon General Scott
Rivkees declared a Public Health Emergency on
March 1st. This was closely followed by a State of
Emergency declared by Governor Ron DeSantis who
issued statewide stay at home orders with guidance to
practice social distancing and other prevention
measures in accordance with national guidelines.2-4 As
of June 4, 2020, all 67 of Florida’s counties had
confirmed cases, with Miami-Dade County having the
highest test positivity rate (10%) and 32 percent of
total cases statewide.1 Other top metropolitan counties
with substantial disease burden included Broward (6%
positivity, 12% of total cases), Palm Beach (8%
positivity, 11% of total cases), Hillsborough (4%
positivity, 4% of total cases), Orange (3% positivity,
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4% of total cases), and Duval counties (3% positivity,
3% of total cases).

amongst those tested across the five locations in the
state.

As the incidence of COVID-19 increased across
Florida, demand for SARS-CoV-2 virus testing also
grew exponentially, leading to the establishment of
state-wide drive-thru testing operations via
partnerships between the Department of Health,
Division of Emergency Management, and the National
Guard. These testing strategies improved and provided
direct and easy access to diagnostic testing to reach the
broader population. Drive-through testing formats had
previously been touted as a safe and effective method
for large volume testing initiatives that directly detect
the pathogen during pandemic situations and have the
benefit of reducing the number of infectious persons
entering and contaminating healthcare establishments
as well as promoting social distancing.5,6

Methods | On May 6, 2020, the Florida Department of
Health in conjunction with community partners, the
Florida National Guard, nurses, paramedics, and
emergency medical technicians, set-up POC antibody
testing at Miami Hard Rock Stadium as part of an
ongoing SARS-CoV-2 drive-thru testing mission, that
previously focused on virologic testing only. Antibody
testing was expanded to three additional drive-thru
sites (Jacksonville, Orlando, and Palm Beach) on May
9, 2020 and one final site, Miami Beach Convention
Center, on May 21, 2020. At each of these five sites,
persons arriving at these testing locations were prescreened and occupation-verified to determine if they
were healthcare workers or first responders. Triaged
healthcare workers and first responders were given the
option to be tested for SARS-CoV-2 antibody, along
with SARS-CoV-2 viral testing via real time, reversetranscription-polymerase chain reaction (rRT-PCR).
All participants tested provided verbal consent. From
May 6, 2020 through June 3, 2020 these testing sites
provided SARS-CoV-2 antibody testing solely to
healthcare workers and first responders. On June 4,
2020, these testing locations expanded antibody
testing to all persons.

Approximately two months after the initial cases were
identified in Florida, point-of-care (POC) SARS-CoV2 antibody testing was offered to healthcare workers
and first responders at five drive-through COVID-19
testing locations to assess the seroprevalence of
antibodies against the SARS-CoV-2 circulating in the
Florida population. Antibody testing has been used in
many diseases previously to track and understand
seroprevalence of disease including Zika virus and
dengue.7-9 For COVID-19, antibody testing can also be
used to identify asymptomatic individuals or
individuals who may have developed mild illness that
didn’t lead to testing, and identify potential donors of
convalescent plasma that could be used to treat
critically ill patients, as the plasma contains antibodies
to COVID-19.10-12 Several SARS-CoV-2 antibody
seroprevalence studies were conducted previously in
the United States, and only one so far has focused on
healthcare workers.13-18 These previous studies
indicated that rates of infection were higher than rates
of reported persons with SARS-CoV-2, likely due to
mild disease and asymptomatic infections that were
undetected, including one study identifying an
antibody seropositivity of nearly 2% in South Florida
in April 2020.14-16
The purpose of this study was to determine the
seroprevalence of COVID-19 in healthcare workers
and first responders at five drive-thru testing sites in
Florida from May 6 through June 3, 2020, using a POC
SARS-CoV-2 antibody test. This report describes the
multi-agency collaborative partnerships and actions
taken to integrate POC antibody testing at established
large-scale COVID-19 testing sites. Further, this study
provided an opportunity to establish a baseline
seroprevalence amongst high-risk, front-line workers
during the COVID-19 emergency response in Florida
and describes racial/ethnic disparities within and

All healthcare workers and first responders tested for
SARS-CoV-2 antibodies completed a laboratory
specimen collection form for the POC serologic test
prior to testing. Data captured on the form included
demographic information such as sex at birth, race,
ethnicity, date of birth, and test result. Healthcare
workers and first responders had whole blood
specimens drawn via venipuncture while they
remained in their vehicles. Specimens were processed
according to manufacturer’s specifications using the
Cellex Inc. qSARS-CoV-2 IgG/IgM Rapid Test.19 The
tests uses SARS-CoV-2 recombinant antigens (S and
N proteins). The Cellex Inc. qSARS-CoV-2 IgG/IgM
Rapid Test reports a percent positive agreement to RTPCR SARS-CoV-2 samples of 93.8% (95% C.I. 88.296.8%) and negative percent agreement of 96.0%
(95% C.I. 92.8-97.8%). Specimen processing was
done onsite and results were returned to participants in
less than one half hour. Test results were subsequently
entered into the Florida Department of Health’s
Counseling Testing and Linkage System (CTLS).
SARS-CoV-2 antibody testing data from these five
drive-thru sites from May 6, 2020 through June 3,
2020 were extracted on June 7, 2020 from CTLS. Test
results were recorded as IgM+, IgM+ and IgG+, IgG+,
positive, negative, or three different results that were
combined as “unknown” in CTLS (invalid,
indeterminate, missing/result in progress). When
analyzing by individual rather than by site we
MATTHIAS ET AL
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combined all possible positive (IgM+, IgM+ and
IgG+, IgG+, and positive) results into one positive
category. Age groups started with 17-29, followed by
10-year age groups up to 69 years of age, and one
collapsed age group of 70-89 years because there were
no positive antibody tests in the 80-89 (n=8) age
group. Race and ethnicity were combined. Ethnicity
took prioritization as persons with Haitian/Creole or
Hispanic/Latino(a) ethnicity were categorized as such
regardless of selection on the race variable (i.e. White
non-Hispanic was categorized as Hispanic/Latino(a)).
Persons selecting White for “race” and “nonHispanic” or “missing” for ethnicity were classified as
White non-Hispanic. Likewise, persons selecting
Black for “race” and “non-Hispanic” or “missing” for
ethnicity were classified as Black non-Hispanic.
Persons selecting any other race/ethnicity beyond
these categories listed were classified as “Other”,
while those selecting none were listed as
missing/unknown.
SARS-CoV-2 antibody test results were stratified by
test site and specimen collection date. Antibody
seropositivity was determined by taking the sum of all
positive test results (IgM+, IgM+ and IgG+, IgG+, and
positive) and dividing by total number of test results.
We determined seropositivity for healthcare workers

and first responders. Odds ratios for the seropositivity
for healthcare workers and first responders were
estimated for sex, race/ethnicity, age group, and
testing location. These odds ratios were adjusted for
testing location (table 2) as well as other demographics
(supplemental table 1) using logistic regression with
Wald’s 95% confidence intervals. All analyses were
performed using SAS Studio v. 3.6 (Cary, N.C.). The
project was reviewed by the Florida Department of
Health Institutional Review Board Office and was
conducted consistent with applicable federal law and
institutional policies.20
Results | Testing began at Miami Hard Rock Stadium
on May 6, 2020 with 47 tests including 5 that were
reactive (1 IgM+ and 4 IgG+) (Figure 1). Testing
seropositivity peaked the next day on May 7, 2020 at
11.1% (8 of 72). When testing capacity expanded to
three additional sites on May 9, 2020: Jacksonville,
Orlando, and Palm Beach, testing peaked on May 12,
2020 with 358 healthcare workers and first responders
tested. The fifth and final site, the Miami Beach
Convention Center, began testing healthcare workers
and first responders on May 21, 2020. On June 4,
2020, these sites stopped limiting testing to healthcare
workers and first responders and were opened to
others.

Figure 1. Cumulative point-of-care (POC) antibody tests performed across all sites by day and corresponding daily
seropositivity, Florida, May-June 2020.
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Table 1. Summary of point-of-care (POC) antibody test results stratified by testing site, Florida, May-June 2020

Antibody Test Result
% Positive
(95% CI)*
Testing Site
IgM+ IgM & IgG+ IgG+ Positive Negative Non-resulted Total
Miami-Hard Rock Stadium
3
5 100
7
1295
18 1428 8.2% (6.7-9.6)
Orlando-Orange County C.C.
5
4
41
0
1734
13 1797 2.8% (2.0-3.6)
Jacksonville-TIAA Bank Field
3
4
36
4
1703
28 1778 2.7% (1.9-3.4)
Palm Beach-FITTEAM Ballpark
0
0
9
3
448
31
491 2.6% (1.2-4.1)
Miami Beach Convention Center
1
0
9
0
272
3
285 3.5% (1.4-5.7)
All Sites
12
13 195
14
5452
93 5779 4.1% (3.6-4.6)
* The sum of all positive results (IgM+, IgM & IgG+, IgG+, and positive) divided by the sum of that number and the negative
results.

Table 2. Point-of-care (POC) antibody test results by persons stratified by demographics and adjusted for testing
location, Florida, May-June 2020

Demographics
Positive Negative
% Positive (95% CI)* Odds Ratio (95% CI) adj Odds Ratio (95% CI)†
Sex at Birth
Female
134
3169
4.1% (3.4-4.8)
1.00 (0.76, 1.32)
1.09 (0.83-1.44)
Male
90
2134
4.0% (3.3-5.0)
Ref
Ref
Missing‡
10
149
6.3% (3.3-11.3)
N/A
N/A
Race/Ethnicity
White non-Hispanic
63
2626
2.3% (1.8-3.0)
Ref
Ref
Black non-Hispanic
40
877
4.4% (3.2-5.9)
1.90 (1.27-2.85)
1.63 (1.08-2.46)
Hispanic/Latino(a)
87
1230
6.6% (5.4-8.1)
2.95 (2.12-4.11)
2.17 (1.50-3.13)
Haitian/Creole
5
49
9.3% (3.6-20.3)
4.25 (1.64-11.04)
3.28 (1.23-8.72)
¶
Other
11
316
3.4% (1.8-6.0)
1.45 (0.76-2.78)
1.53 (0.80-2.95)
Missing‡
16
365
4.2% (2.6-6.8)
N/A
N/A
Age group (years)
17-29
34
674
4.8% (3.4-6.7)
Ref
Ref
30-39
48
1412
3.3% (2.5-4.3)
0.67 (0.43-1.06)
0.67 (0.43-1.05)
40-49
46
1298
3.4% (2.6-4.5)
0.70 (0.44-1.11)
0.69 (0.44-1.09)
50-59
65
1282
4.8% (3.8-6.1)
1.00 (0.66-1.55)
0.96 (0.62-1.47)
60-69
31
633
4.7% (3.3-6.6)
0.97 (0.59-1.60)
0.94 (0.57-1.56)
70-89
9
109
7.6% (3.9-14.0)
1.64 (0.76-3.51)
1.67 (0.77-3.63)
Missing‡
1
44
2.2% (0.0-12.6)
N/A
N/A
Total‡
234
5452
4.1% (3.6-4.7)
N/A
N/A
* The sum of all positive results (IgM+, IgM & IgG+, IgG+, and positive) divided by the sum of that number and the
negative results. † Odds ratio adjusted for testing site. ‡ Odds ratio and adjusted odds ratios not calculated for
totals and missing demographic values. Non-resulted tests were excluded. ¶ Persons of other race/ethnicity were
individuals who identified as either “other” as a race or identified as a different race/ethnicity not listed above.
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In total, 5,779 SARS-CoV-2 POC antibody tests were
performed among healthcare workers and first
responders in Florida at five drive-thru testing sites
from May 6, 2020 through June 3, 2020. Of the 5,686
(98.4%) who had a reported result, 5,452 (95.9%)
were negative and 234 (4.1%) were positive for
SARS-CoV-2 antibodies. The highest SARS-CoV-2
antibody positivity rate, 8.2%, was at the Miami Hard
Rock Stadium. The remaining test sites had a
seropositivity for SARS-CoV-2 ranging between 2.6%
and 3.5%. Although more women than men were
tested for SARS-CoV-2 antibodies, seropositivity
(4.1% vs. 4.0%) did not differ by sex (Table 2). Test
positivity ranged from 3.3% to 4.8% for persons aged
17-69 years but for those aged 70-89 years it was 7.6%
(9 of 118) (95% C.I. 3.9-14.0%). Seropositivity was
higher for persons with Haitian/Creole ethnicity (9.3%
95% C.I. 3.6-20.3%), Hispanic/Latino ethnicity (6.6%
95% C.I. 5.4-8.1%), and Black non-Hispanic persons
(4.4% 95% C.I. 3.2-5.9%) than for white non-Hispanic
persons (2.3% 95% C.I. 1.8-3.0%).
Even after accounting for the testing location,
healthcare workers and first responders of
Haitian/Creole ethnicity (aOR 3.28 95% C.I. 1.238.72), Hispanic/Latino(a) ethnicity (aOR 2.17 95%
C.I. 1.50-3.13), and Black non-Hispanic persons (aOR
1.63 95% C.I. 1.08-2.46) had higher odds of testing
positive for SARS-CoV-2 antibodies compared to
white non-Hispanic persons (Table 2). Persons testing
at the Miami Hard Rock Stadium had 2.2 (95% C.I.
1.48-3.39) times higher odds of testing positive for
SARS-CoV-2 antibodies than persons at other sites,
after adjusting for age, race/ethnicity, and sex
(supplemental table 1).
Discussion | Seropositivity among healthcare workers
and first responders was generally low in Florida in
May 2020, averaging 4%; but at one site, the Miami
Hard Rock Stadium, positivity was nearly 8%. This
suggests disease transmission was widespread in
Florida at that time but focally clustered in some
geographic areas. However, this local variation in
seropositivity did not differ greatly from the reported
epidemiological burden of COVID-19 in Florida
through June 3, 2020 although somewhat surprisingly,
because the RT-PCR positivity was higher in the
Counties at the same time, the Miami Beach and Palm
Beach locations had seropositivity no different from
those of Orlando and Jacksonville.1 When compared
to a previous antibody study among South Floridians
in April, the antibody test positivity from this study in
May and June among healthcare workers in South
Florida, particularly at the Hard Rock testing site, was
higher than in previous study.16 Moreover, the
seropositivity observed among healthcare workers and
first responders in this study was similar to that of
healthcare workers at locations across the country

tested in a similar timeframe.18 After accounting for
testing location, race/ethnicity disparities in
seropositivity for SARS-CoV2 antibodies were
observed among healthcare workers and first
responders in this study similar to the disparities
observed among healthcare workers and nationally.5,17
One of the strengths of this evaluation was its scope
and breadth in comparison to other antibody studies in
the United States and around the world as it included
more geographically diverse testing sites and more
persons tested.13-18 Although healthcare workers and
first responders are at potentially increased risk for
SARS-CoV-2 infection, in Florida, their seropositivity
for SARS-CoV-2 antibodies did not reach the levels
observed in a small study in Boston (31.5%) or a study
involving the crew of one aircraft carrier (59.7%).15,17
The seropositivity rates in this study were closer to
those observed in the general population in two
California seroprevalence studies from April, with the
exception of the Miami Hard Rock Stadium site which
was nearly double at 8.2% of 1,395 tests.13-14
One of the main limitations of this study was the
reported performance characteristics of the rapid POC
antibody test to determine the presence of SARS-CoV2 antibodies. The Cellex Inc. qSARS-CoV-2 IgG/IgM
rapid test used was approved under the United States
Food and Drug Administration’s (FDA) Emergency
Use Authorization (EUA); the test’s performance
specifications had a reported positive agreement with
clinical specimens of 93.8% and negative agreement
of 96.0%.19 The negative agreement is of concern for
areas with a low prevalence because false positive
results could account for a large proportion of the
positive test results. However, for higher prevalence
sites the even lower positive agreement may mean that
more true positives were missed (underestimating the
burden of disease), especially if the real-world use of
these tests had lower sensitivity than during
validation.21 Additional guidance after the initiation of
this project was developed and advised using an
orthogonal testing algorithm for persons testing
positive by antibody tests, which could lead to
improved positive predictive value of this test.22 It
should be noted, few antibody tests are POC, available
at-scale, and have an FDA EUA, making them not
feasible for this testing mission, nor possible for an
orthogonal antibody testing algorithm.
One remaining limitation of this study is its lack of
generalizability as it focused entirely on healthcare
workers and first responders in Florida, which limits
the ability to extrapolate our data, as the risk of
infection in this cohort is not likely the same as in the
general population .13-14 However, with the expansion
of these same testing sites to the general public on June
4, 2020, future analyses may allow for generalizability
MATTHIAS ET AL
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and comparison between the general public and this
occupational group.
As part of this evaluation, we were able to show that
POC SARS-CoV-2 antibody testing was feasible atscale, sustainable, and replicable. It is worth noting
that the resources needed, including labor (most sites
needed multiple personnel for phlebotomy, data entry,
testing, etc.) and materials (test kits, personal
protective equipment, venipuncture supplies, and
more) each and every day, are not trivial. One big
benefit of these tests is that they can be performed
outside of clinical laboratories. If the test could be
shown to achieve similar results using fingerstick
instead of venipuncture, it would dramatically reduce
the skilled resources needed to conduct widespread
screening. This use of drive-thru testing sites and rapid
antibody tests may be one potential way for agencies
to meet some of the demands for SARS-CoV-2
serological testing.23-26
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Supplemental Table 1. Logistic Regression Model adjusting for all demographics and testing sites in one model for
SARS-CoV-2 point-of-care (POC) antibody seropositivity, Florida, May-June 2020*

Demographic/Testing Site
Adj. Odds Ratio
95% Confidence Intervals
Race/Ethnicity
White non-Hispanic
Ref
--Black non-Hispanic
1.64
1.08
2.49
Hispanic/Latino(a)
2.19
1.51
3.18
Haitian/Creole
3.50
1.30
9.42
Other†
1.57
0.82
3.04
Age Group
17-29
Ref
--30-39
0.73
0.45
1.17
40-49
0.66
0.40
1.07
50-59
1.01
0.64
1.59
60-69
1.07
0.63
1.82
70-89
1.77
0.75
4.20
Sex at Birth
Female
1.04
0.77
1.39
Male
Ref
--Testing Site
Jacksonville
Ref
--Palm Beach
0.78
0.39
1.54
Miami Hard Rock
2.24
1.49
3.39
Miami Beach
1.04
0.50
2.16
Orlando
0.98
0.64
1.50
2
* The likelihood ratio rejected the null hypothesis (X =84.08; P<0.0001) for the logistic
regression model’s goodness of fit. McFadden’s pseudo R2 for the model was 0.05. †Persons
of other race/ethnicity were individuals who identified as either “other” as a race or identified
as a different race/ethnicity not listed above.
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